NVSS vital statistics rapid release: provisional drug overdose death counts 2022. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm.
Abuse NIoD. Florida: opioid-involved deaths and related harms National Institute on Drug Abuse Website2020. https://www.drugabuse.gov/drug-topics/opioids/opioid-summaries-by-state/florida-opioid-involved-deaths-related-harms
McCarthy NL, Baggs J, See I, Reddy SC, Jernigan JA, Gokhale RH, et al. Bacterial infections associated with substance use disorders, large cohort of United States Hospitals, 2012–2017. Clin Infect Dis. 2020;71(7):e37–44.
Morris MD, Shiboski S, Bruneau J, Hahn JA, Hellard M, Prins M, et al. Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: the InC3 collaboration. Clin Infect Dis. 2017;64(7):860–9.
Article CAS PubMed PubMed Central Google Scholar
Hall EW, Rosenberg ES, Jones CM, Asher A, Valverde E, Bradley H. Estimated number of injection-involved drug overdose deaths, United States, 2000–2018. Drug Alcohol Depend. 2022;234: 109428.
Coye AE, Bornstein KJ, Bartholomew TS, Li H, Wong S, Janjua NZ, et al. Hospital costs of injection drug use in Florida. Clin Infect Dis. 2021;72(3):499–502.
Coffa D, Snyder H. Opioid use disorder: medical treatment options. Am Fam Physician. 2019;100(7):416–25.
Bell J, Strang J. Medication treatment of opioid use disorder. Biol Psychiatry. 2020;87(1):82–8.
Article CAS PubMed Google Scholar
Hill LG, Loera LJ, Evoy KE, Renfro ML, Torrez SB, Zagorski CM, et al. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA. Addiction. 2021;116(6):1505–11.
Pham S, Haigh A, Barrett E. Statewide availability of buprenorphine/naloxone in acute care hospitals. J Addict Med. 2021;16(1):e48–51.
Williams AR, Nunes EV, Bisaga A, Levin FR, Olfson M. Development of a cascade of care for responding to the opioid epidemic. Am J Drug Alcohol Abuse. 2019;45(1):1–10.
Article PubMed PubMed Central Google Scholar
Upadhyaya A, Marks LR, Schwarz ES, Liang SY, Durkin MJ, Liss DB. Care cascade for patients with opioid use disorder and serious injection related infections. Toxicol Commun. 2021;5(1):6–10.
Article PubMed PubMed Central Google Scholar
Levesque JF, Harris MF, Russell G. Patient-centred access to health care: conceptualising access at the interface of health systems and populations. Int J Equity Health. 2013;12:18.
Article PubMed PubMed Central Google Scholar
Kolb E, Rueth M. Patient satisfaction with clinic-based medication pick up: addressing pharmacy-level challenges to buprenorphine access. J Opioid Manag. 2021;17(7):77–86.
Cooper HLF, Cloud DH, Young AM, Freeman PR. When prescribing isn’t enough—pharmacy-level barriers to buprenorphine access. N Engl J Med. 2020;383(8):703–5.
Kazerouni NJ, Irwin AN, Levander XA, Geddes J, Johnston K, Gostanian CJ, et al. Pharmacy-related buprenorphine access barriers: an audit of pharmacies in counties with a high opioid overdose burden. Drug Alcohol Depend. 2021;224: 108729.
Article CAS PubMed Google Scholar
Hill LG, Loera LJ, Torrez SB, Puzantian T, Evoy KE, Ventricelli DJ, et al. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states. Drug Alcohol Depend. 2022;237:109518.
Article CAS PubMed Google Scholar
Cooper HL, Cloud DH, Freeman PR, Fadanelli M, Green T, Van Meter C, et al. Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: a case study of the rural risk environment in Appalachian Kentucky. Int J Drug Policy. 2020;85:102701.
Article PubMed PubMed Central Google Scholar
Textor L, Ventricelli D, Aronowitz SV. “Red Flags” and “Red Tape”: Telehealth and pharmacy-level barriers to buprenorphine in the United States. Int J Drug Policy. 2022;105: 103703.
Ventricelli DJ, Mathis SM, Foster KN, Pack RP, Tudiver F, Hagemeier NE. Communication experiences of DATA-waivered physicians with community pharmacists: a qualitative study. Subst Use Misuse. 2020;55(3):349–57.
Federal Guidelines for Opioid Treatment Programs. 2015.
Pham S, Haigh A, Barrett E. Statewide availability of buprenorphine/naloxone in acute care hospitals. J Addict Med. 2022;16(1):e48–51.
Pourmand A, Beisenova K, Shukur N, Tebo C, Mortimer N, Mazer-Amirshahi M. A practical review of buprenorphine utilization for the emergency physician in the era of decreased prescribing restrictions. Am J Emerg Med. 2021;48:316–22.
Office C. Pharmacies in (Miami-Dade County, Broward County, Palm Beach County), Florida CountyOffice.org: CountyOffice.org. 2022. https://www.countyoffice.org/fl-miami-dade-county-pharmacy/.
Directory AH. American Hospital Directory American Hospital Directory Website: American Hospital Directory; 2021. https://www.ahd.com.
Coye AE, Bornstein KJ, Bartholomew TS, Hua L, Wong S, Janjua NZ, et al. Hospital costs of injection drug use in Florida. Clin Infect Dis. 2020;72(3):499–502.
Article PubMed Central Google Scholar
Serota DP, Bartholomew TS, Tookes HE. Evaluating differences in opioid and stimulant use-associated infectious disease hospitalizations in Florida, 2016–2017. Clin Infect Dis. 2021;73(7):e1649–57.
Velez CM, Nicolaidis C, Korthuis PT, Englander H. “It’s been an experience, a life learning experience”: a qualitative study of hospitalized patients with substance use disorders. J Gen Intern Med. 2017;32(3):296–303.
National Academies of Sciences, Engineering, and Medicine. Opportunities to improve opioid use disorder and infectious disease services: integrating responses to a dual epidemic. Washington, DC: The National Academies Press; 2020. https://doi.org/10.17226/25626
Davenport ES, Arnett SJ, Nichols MA, Miller ML. Indiana community pharmacist preceptors’ knowledge and perceptions of medication-assisted treatment. J Am Pharm Assoc (2003). 2020;60(3S):S20-S8 e4.
Muzyk A, Smothers ZPW, Collins K, MacEachern M, Wu LT. Pharmacists’ attitudes toward dispensing naloxone and medications for opioid use disorder: a scoping review of the literature. Subst Abus. 2019;40(4):476–83.
Article PubMed PubMed Central Google Scholar
Englander H, Jones A, Krawczyk N, Patten A, Roberts T, Korthuis PT, et al. A taxonomy of hospital-based addiction care models: a scoping review and key informant interviews. J Gen Intern Med. 2022;37(11):2821–33.
Lewer D, Eastwood B, White M, Brothers TD, McCusker M, Copeland C, et al. Fatal opioid overdoses during and shortly after hospital admissions in England: a case-crossover study. PLoS Med. 2021;18(10): e1003759.
Article CAS PubMed PubMed Central Google Scholar
Bureau USC. Quick facts, population data 2020. https://www.census.gov/quickfacts/fact/table/palmbeachcountyflorida,palmbeachtownflorida,palmbeachgardenscityflorida,miamidadecountyflorida/PST040221.
Buprenorphine practitioner locator substance abuse and mental health services administration: substance abuse and mental health services administration; 2021. https://www.samhsa.gov/medication-assisted-treatment/find-treatment/treatment-practitioner-locator.
Administration SAaMHS. Opioid treatment program directory substance abuse and mental health services administration substance abuse and mental health services administration 2021. https://dpt2.samhsa.gov/treatment/.
U.S. Department of Health and Human Services OoIG. Geographic disparities affect access to buprenorphine services for opioid use disorder oig.hhs.gov: U.S. Department of Health and Human Services; 2020. https://oig.hhs.gov/oei/reports/oei-12-17-00240.pdf.
Hansen H, Siegel C, Wanderling J, DiRocco D. Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City. Drug Alcohol Depend. 2016;164:14–21.
Article PubMed PubMed Central Google Scholar
Kariisa M, Davis NL, Kumar S, Seth P, Mattson CL, Chowdhury F, et al. Vital signs: drug overdose deaths, by selected sociodemographic and social determinants of health characteristics—25 states and the District of Columbia, 2019–2020. MMWR Morb Mortal Wkly Rep. 2022;71(29):940–7.
留言 (0)